MLTX.US MoonLake Immunotherapeutics

Healthcare Biotechnology USA Stocks
12.50 USD
Close of Nov 15, 2026
9.46 23.29
Market cap
USD 1.06B
P/E
-
P/B
2.79x
ROE
-73.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MLTX.US undervalued?

Graham number

The Graham number of MoonLake Immunotherapeutics cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MoonLake Immunotherapeutics fundamental analysis

No fundamental analysis for MoonLake Immunotherapeutics yet.

MoonLake Immunotherapeutics stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquarte…

Full company profile